SF-2523

• CAT Number: R066999
• CAS Number: 1174428-47-7
• Molecular Formula: C₁₉H₁₇NO₅S
• Molecular Weight: 371.41
• Purity: ≥95%
• Synonyms: 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(4-morpholinyl)-7H-thieno[3,2-b]pyran-7-one
• Target: Epigenetics
• Storage: -20°C
• IUPAC Name: 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-morpholin-4-ylthieno[3,2-b]pyran-7-one
• InChI: InChI=1S/C19H17NO5S/c21-14-10-17(20-3-5-22-6-4-20)25-18-13(11-26-19(14)18)12-1-2-15-16(9-12)24-8-7-23-15/h1-2,9-11H,3-8H2
• InChIKey: BYTKNUOMWLJVNQ-UHFFFAOYSA-N
• SMILES: C1COCCN1C2=CC(=O)C3=C(O2)C(=CS3)C4=CC5=C(C=C4)OCCO5

SF-2523（Cat No.:R066999）is a dual inhibitor of both PI3K and BRD4, two critical targets involved in cancer progression and survival. By simultaneously inhibiting PI3K, part of the PI3K/Akt/mTOR pathway, and BRD4, a bromodomain protein that regulates gene transcription, SF-2523 effectively suppresses cancer cell proliferation and promotes apoptosis. It has demonstrated promising anticancer effects, particularly in malignancies with dysregulated PI3K signaling or overactive MYC oncogene. SF-2523 is used in research to explore the synergistic therapeutic potential of targeting both PI3K signaling and epigenetic regulation in cancer.

Reference

1.Andrews, F.H.S., A.R.,Joshi, S.,Smith, C.A., et al. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 114(7), E1072-E1080 (2017).